| pubmed-article:19672152 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19672152 | lifeskim:mentions | umls-concept:C0034656 | lld:lifeskim |
| pubmed-article:19672152 | lifeskim:mentions | umls-concept:C0281361 | lld:lifeskim |
| pubmed-article:19672152 | lifeskim:mentions | umls-concept:C0045093 | lld:lifeskim |
| pubmed-article:19672152 | lifeskim:mentions | umls-concept:C0282460 | lld:lifeskim |
| pubmed-article:19672152 | lifeskim:mentions | umls-concept:C1696465 | lld:lifeskim |
| pubmed-article:19672152 | lifeskim:mentions | umls-concept:C0298619 | lld:lifeskim |
| pubmed-article:19672152 | lifeskim:mentions | umls-concept:C0205179 | lld:lifeskim |
| pubmed-article:19672152 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:19672152 | pubmed:dateCreated | 2009-8-12 | lld:pubmed |
| pubmed-article:19672152 | pubmed:abstractText | LY293111 (LY) is a novel oral anticancer agent with leukotriene B4 receptor antagonist and peroxisome proliferator-activated receptor gamma agonist properties, producing promising results alone and in combination with gemcitabine in pancreatic cancer xenograft models. A phase I study proved that the combination (gemcitabine plus LY) is safe and well tolerated. | lld:pubmed |
| pubmed-article:19672152 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19672152 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19672152 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19672152 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19672152 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19672152 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19672152 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19672152 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19672152 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19672152 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19672152 | pubmed:issn | 1528-9117 | lld:pubmed |
| pubmed-article:19672152 | pubmed:author | pubmed-author:RichardsD ADA | lld:pubmed |
| pubmed-article:19672152 | pubmed:author | pubmed-author:SpitzerGG | lld:pubmed |
| pubmed-article:19672152 | pubmed:author | pubmed-author:ThomasJ PJP | lld:pubmed |
| pubmed-article:19672152 | pubmed:author | pubmed-author:OettleHH | lld:pubmed |
| pubmed-article:19672152 | pubmed:author | pubmed-author:ChiaG AGA | lld:pubmed |
| pubmed-article:19672152 | pubmed:author | pubmed-author:VervenneW LWL | lld:pubmed |
| pubmed-article:19672152 | pubmed:author | pubmed-author:SaifMuhammad... | lld:pubmed |
| pubmed-article:19672152 | pubmed:author | pubmed-author:Visseren-Grul... | lld:pubmed |
| pubmed-article:19672152 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:19672152 | pubmed:volume | 15 | lld:pubmed |
| pubmed-article:19672152 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19672152 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19672152 | pubmed:pagination | 339-43 | lld:pubmed |
| pubmed-article:19672152 | pubmed:meshHeading | pubmed-meshheading:19672152... | lld:pubmed |
| pubmed-article:19672152 | pubmed:meshHeading | pubmed-meshheading:19672152... | lld:pubmed |
| pubmed-article:19672152 | pubmed:meshHeading | pubmed-meshheading:19672152... | lld:pubmed |
| pubmed-article:19672152 | pubmed:meshHeading | pubmed-meshheading:19672152... | lld:pubmed |
| pubmed-article:19672152 | pubmed:meshHeading | pubmed-meshheading:19672152... | lld:pubmed |
| pubmed-article:19672152 | pubmed:meshHeading | pubmed-meshheading:19672152... | lld:pubmed |
| pubmed-article:19672152 | pubmed:meshHeading | pubmed-meshheading:19672152... | lld:pubmed |
| pubmed-article:19672152 | pubmed:meshHeading | pubmed-meshheading:19672152... | lld:pubmed |
| pubmed-article:19672152 | pubmed:meshHeading | pubmed-meshheading:19672152... | lld:pubmed |
| pubmed-article:19672152 | pubmed:meshHeading | pubmed-meshheading:19672152... | lld:pubmed |
| pubmed-article:19672152 | pubmed:meshHeading | pubmed-meshheading:19672152... | lld:pubmed |
| pubmed-article:19672152 | pubmed:meshHeading | pubmed-meshheading:19672152... | lld:pubmed |
| pubmed-article:19672152 | pubmed:meshHeading | pubmed-meshheading:19672152... | lld:pubmed |
| pubmed-article:19672152 | pubmed:meshHeading | pubmed-meshheading:19672152... | lld:pubmed |
| pubmed-article:19672152 | pubmed:meshHeading | pubmed-meshheading:19672152... | lld:pubmed |
| pubmed-article:19672152 | pubmed:meshHeading | pubmed-meshheading:19672152... | lld:pubmed |
| pubmed-article:19672152 | pubmed:articleTitle | Randomized double-blind phase II trial comparing gemcitabine plus LY293111 versus gemcitabine plus placebo in advanced adenocarcinoma of the pancreas. | lld:pubmed |
| pubmed-article:19672152 | pubmed:affiliation | Yale Cancer Center, Yale University School of Medicine, New Haven, CT, USA. wasif.saif@yale.edu | lld:pubmed |
| pubmed-article:19672152 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:19672152 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:19672152 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:19672152 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:19672152 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:19672152 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:19672152 | lld:pubmed |
